Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.
Cell & Gene Therapy
European agencies catch up with speedier regulatory pathways for CGTs in the US
Inborn errors of metabolism elicit unique challenges for therapy development
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance
Novartis acquires Kate Therapeutics to advance gene therapies
FDA shares additional draft guidance on CGTs
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
Resolution scores $83m to develop macrophage cell therapies
